HE4 ovarian cancer biomarker benefits from global branding campaign by Fujirebio Diagnostics

STINSON is working with Fujirebio Diagnostics to show physicians around the world how to “Take The Right Path” with its novel HE4 biomarker for ovarian cancer.

Country market managers and distributors in Europe, Asia, and the U.S are executing the campaign.

Tactical applications of the core brand platform include sales brochures, journal ads, convention displays, touch-screen displays, direct mail, and e-marketing.

The goal of the campaign is to promote the HE4 test to gynecologic oncologists and OB/GYNs– and to encourage referrals of ovarian cancer patients for surgery performed by a gynecologic oncologist or a surgeon with specialized training in the management of ovarian cancer.

Leading researchers say that roughly 20 percent of women will be diagnosed with an ovarian cyst or tumor at some point in their lives, but only a small percentage of these women will be diagnosed with ovarian cancer. The problem, experts say, is that current methods for distinguishing benign ovarian tumors from malignant ones are limited, and as a result women must undergo surgery without an accurate assessment as to their risk for having ovarian cancer prior to their surgery.

With better testing, patients with (or at risk for) ovarian cancer can receive the right care from the right physician.

Congratulations to Fujirebio Diagnostics for being named Life Sciences Company of the Year by the Eastern Technology Council.

You can also read more about STINSON Brand Innovation and our international branding assignments in the “Global Issue” of our Accelerate newsletter.